Show simple item record

dc.contributor.authorMarwick, TH
dc.contributor.authorWhitmore, K
dc.contributor.authorNicholls, SJ
dc.contributor.authorStanton, T
dc.contributor.authorMitchell, G
dc.contributor.authorTonkin, A
dc.contributor.authorBlizzard, C
dc.contributor.authorNeil, A
dc.contributor.authorJones, C
dc.contributor.authorWatts, GF
dc.date.accessioned2020-01-02T04:26:02Z
dc.date.available2020-01-02T04:26:02Z
dc.date.issued2018
dc.identifier.issn0002-8703
dc.identifier.doi10.1016/j.ahj.2017.09.011
dc.identifier.urihttp://hdl.handle.net/10072/389989
dc.description.abstractBackground: The lifetime risk of coronary artery disease (CAD) is doubled in people with a family history of premature disease, yet this risk is not captured in most 5- or 10-year risk assessment algorithms. Coronary artery calcium scoring (CCS) is a marker of subclinical CAD risk, which has been shown in observational studies to provide prognostic information that is incremental to clinical assessment; is relatively inexpensive; and is performed with a small radiation dose. However, the use of CCS in guiding prevention is not strongly supported by guidelines. Showing definitive evidence of the efficacy and cost-effectiveness of CCS is therefore of importance. Study design: The proposed randomized controlled trial of the use of CCS will be targeted to 40- to 70-year-old first-degree relatives of patients with CAD onset <60 years old or second-degree relatives of patients with onset <50 years old. Control patients will undergo standard risk scoring and be blinded to CCS results. In the intervention group, primary prevention in patients undergoing CCS will be informed by this score. At 3 years, effectiveness will be assessed on change in plaque volume at computed tomography coronary angiography, the extent of which has been strongly linked to outcome. The CAUGHT-CAD trial will provide evidence to inform the guidelines regarding the place of CCS in decision making regarding primary prevention of patients with a family history of premature disease.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom22
dc.relation.ispartofpageto30
dc.relation.ispartofjournalAmerican Heart Journal
dc.relation.ispartofvolume199
dc.subject.fieldofresearchCardiorespiratory Medicine and Haematology
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode1102
dc.subject.fieldofresearchcode1117
dc.titleRationale and design of a trial to personalize risk assessment in familial coronary artery disease
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMarwick, TH; Whitmore, K; Nicholls, SJ; Stanton, T; Mitchell, G; Tonkin, A; Blizzard, C; Neil, A; Jones, C; Watts, GF, Rationale and design of a trial to personalize risk assessment in familial coronary artery disease, American Heart Journal, 2018, 199, pp. 22-30
dcterms.dateAccepted2017-09-13
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated2020-01-02T04:22:36Z
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2018 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorStanton, Tony


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record